Literature DB >> 2820854

Negative schizophrenic symptomatology and the PCP (phencyclidine) model of schizophrenia.

D C Javitt1.   

Abstract

Amphetamine induced psychosis has for the past 30 years provided a useful model for the study of schizophrenia. The amphetamine model, however, has been shown to have a number of shortcomings including an inability to model the deficit symptoms of schizophrenia. PCP (phencyclidine) has been shown to be capable of inducing a schizophreniform psychosis consisting of both productive and defict symptomatology. PCP induced psychosis, therefore, may provide a useful model of schizophrenia. This paper reviews the literature concerning the PCP model of schizophrenia and provides some independent confirmation of the ability of PCP to modulate mesocortical dopaminergic activity. Since PCP appears to mediate its CNS effects via a subclass of glutamate receptors, a possible glutamate theory of schizophrenia is proposed.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2820854

Source DB:  PubMed          Journal:  Hillside J Clin Psychiatry        ISSN: 0193-5216


  76 in total

1.  Meta-analysis of the efficacy of adjunctive NMDA receptor modulators in chronic schizophrenia.

Authors:  Surendra P Singh; Vidhi Singh
Journal:  CNS Drugs       Date:  2011-10-01       Impact factor: 5.749

Review 2.  GABAergic interneuron origin of schizophrenia pathophysiology.

Authors:  Kazu Nakazawa; Veronika Zsiros; Zhihong Jiang; Kazuhito Nakao; Stefan Kolata; Shuqin Zhang; Juan E Belforte
Journal:  Neuropharmacology       Date:  2011-01-26       Impact factor: 5.250

3.  Modulation of MK-801 response by dopaminergic agents in mice.

Authors:  A Verma; S K Kulkarni
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

Review 4.  Postmortem investigations of the pathophysiology of schizophrenia: the role of susceptibility genes.

Authors:  William R Perlman; Cynthia Shannon Weickert; Mayada Akil; Joel E Kleinman
Journal:  J Psychiatry Neurosci       Date:  2004-07       Impact factor: 6.186

Review 5.  N-methyl-d-aspartate (NMDA) receptor dysfunction or dysregulation: the final common pathway on the road to schizophrenia?

Authors:  Joshua T Kantrowitz; Daniel C Javitt
Journal:  Brain Res Bull       Date:  2010-04-24       Impact factor: 4.077

6.  Alterations in brain extracellular dopamine and glycine levels following combined administration of the glycine transporter type-1 inhibitor Org-24461 and risperidone.

Authors:  Katalin Nagy; Bernadett Marko; Gabriella Zsilla; Peter Matyus; Katalin Pallagi; Geza Szabo; Zsolt Juranyi; Jozsef Barkoczy; Gyorgy Levay; Laszlo G Harsing
Journal:  Neurochem Res       Date:  2010-08-20       Impact factor: 3.996

7.  Amphiphysin I but not dynamin I nor synaptojanin mRNA expression increased after repeated methamphetamine administration in the rat cerebrum and cerebellum.

Authors:  Mitsuko Hamamura; Jiro Okouchi; Hidetoshi Ozawa; Yoshihiko Kimuro; Akiko Iwaki; Yasuyuki Fukumaki
Journal:  J Neural Transm (Vienna)       Date:  2012-12-08       Impact factor: 3.575

8.  Cortical expression of glial fibrillary acidic protein and glutamine synthetase is decreased in schizophrenia.

Authors:  Amy E Steffek; Robert E McCullumsmith; Vahram Haroutunian; James H Meador-Woodruff
Journal:  Schizophr Res       Date:  2008-06-17       Impact factor: 4.939

9.  Effects of combined 5-HT2A and cannabinoid receptor modulation on a schizophrenia-related prepulse inhibition deficit in mice.

Authors:  Adriana M Marques; Michele V Macena; Aline R Cardoso; Camila S O Hammes; Fernanda M L Pinheiro; Newton G Castro; Gilda A Neves
Journal:  Psychopharmacology (Berl)       Date:  2020-02-24       Impact factor: 4.530

Review 10.  Cannabis and psychosis/schizophrenia: human studies.

Authors:  Deepak Cyril D'Souza; Richard Andrew Sewell; Mohini Ranganathan
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2009-07-16       Impact factor: 5.270

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.